Health Care

Cadrenal Therapeutics’ Phase 2 success with CAD‑1005 shows promise for treating ESRD‑related thromboembolism, sparking investor interest amid biotech volatility.

ADMA Biologics delivers record FY 2025 revenue and earnings growth, fueled by ASCENIV and a promising SG‑001 pipeline, while disciplined capital strategy drives shareholder value.

InflaRx NV: German biopharma firm advancing monoclonal antibody drugs for inflammatory diseases, with volatile share price yet strong investor confidence and upcoming 2026 investor conference.

Explore IDEXX Laboratories’ high valuation, leadership shifts, AI risks, and tariff impacts—find out if the diagnostic leader can sustain growth.

Viatris’s FDA‑accepted MR‑141 could unlock a new, non‑invasive presbyopia market, diversifying earnings and boosting stock value—will it succeed?

Pentixapharm Holding AG stock hits €2.175 on Xetra, amid mid‑year volatility but steady clinical progress—investors eye next breakthrough for future upside.

Explore Cyclopharm Ltd’s radiopharmaceutical strategy—focus on lung & cancer imaging, current market stats, and future growth prospects.

MedMira Inc. reports a tough quarter, with its TSX stock hovering near $0.07 and a negative P/E of –12.07, yet it continues pushing next‑generation diagnostic tech worldwide.

BioCardia Inc. (BIOC) is a U.S. biotech focused on cardiovascular therapies, with a $12 M market cap and current negative P/E. No new news yet—watch regulatory filings and earnings for growth clues.

Explore Evolent Health’s Q4 2025 earnings: $468.7 m revenue, 30 % growth, $151 m adjusted EBITDA, and a 2026 outlook with projected margin expansion and new high‑profile health‑plan partnerships.